Hoth Therapeutics, Inc.
HOTH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.03 | -0.08 | -0.09 |
| FCF Yield | -11.16% | -15.39% | -28.51% | -37.18% |
| EV / EBITDA | -3.53 | -2.92 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | -49.49% | -22.53% | -30.05% | -34.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.61 | 1.08 | 0.80 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -5.05% | 14.89% | -37.48% | -24.07% |
| Safety | ||||
| Net Debt / EBITDA | 1.91 | 4.09 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |